Advanced search
Publication Cover
OncoImmunology Volume 4, 2015 - Issue 7
Submit an article Journal homepage
1,791
Views
12
CrossRef citations to date
0
Altmetric
Author's View

Kick-starting the cancer-immunity cycle by targeting CD40

P EllmarkAlligator Bioscience AB; Lund, Sweden;Department of Immunotechnology; Lund University; Lund, SwedenCorrespondence[email protected]
,
S M MangsboDepartment of Immunology, Genetics and Pathology; Uppsala University; Uppsala, Sweden
,
C FurebringAlligator Bioscience AB; Lund, Sweden
,
T H TöttermanDepartment of Immunology, Genetics and Pathology; Uppsala University; Uppsala, Sweden
&
P NorlénAlligator Bioscience AB; Lund, Sweden
Article: e1011484 | Received 22 Dec 2014, Accepted 21 Jan 2015, Published online: 17 Jun 2015

References

  • Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer 2014; 111:2214-9; PMID:25211661; http://dx.doi.org/10.1038/bjc.2014.348.
  • Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.doi.org/10.1016/j.immuni.2013.07.012.
  • Mangsbo SM, Broos S, Fletcher E, Veitonmaki N, Furebring C, Dahlen E, Norlen P, Lindstedt M, Totterman TH, Ellmark P. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T cell dependent tumor immunity. Clin Cancer Res 2015; 21:1115-26. pii: clincanres.0913.2014.
  • Vonderheide RH1, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013;19 :1035-43; PMID:23460534; http://dx.doi.org/10.1158/1078-0432.CCR-12-2064.
  • Jackaman C, Lew AM, Zhan Y, Allan JE, Koloska B, Graham PT, Robinson BW, Nelson DJ. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol 2008;20:1467-79; PMID:18824504; http://dx.doi.org/10.1093/intimm/dxn104.
  • Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res 2011; 17:2270-80; PMID:21389097; http://dx.doi.org/10.1158/1078-0432.CCR-10-2888.
  • Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Tötterman TH, Mangsbo SM. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res 2014; 2:80-90; PMID:24778163; http://dx.doi.org/10.1158/2326-6066.CIR-13-0067.
  • Marabelle A, Kohrt H, Caux C, Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014; 20: 1747-56; PMID:24691639; http://dx.doi.org/10.1158/1078-0432.CCR-13-2116.
  • Furness AJ, Vargas FA, Peggs KS, Quezada SA. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol 2014; 35:290-8; PMID:24953012; http://dx.doi.org/10.1016/j.it.2014.05.002.
  • Zippelius A, Schreiner J, Herzig P2, Müller P. Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol Res. 2015; 3: 236-44.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.